Key facts
- ThirtyFiveBio’s last known valuation is $39.5M (Apr 2021).
- It has raised $27.7M; the latest was Early Stage VC in Apr 2025.
- Notable investors include Innovate UK, Canaan Partners, AbbVie Ventures, M2M (Consulting Services (B2B)), Mayewell Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ThirtyFiveBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ThirtyFiveBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ThirtyFiveBio
Developer of novel genetically and pharmacologically validated protein modulators designed to treat severe gastrointestinal diseases. The company's modulators offer a fully embedded drug discovery program to identify contemporary small-molecule modulators of the protein with expected utility across a broad spectrum of digestive system malignancies, enabling patients to prevent GPR35 signaling and tumor growth-derived cancer models.
- Sector
- Healthcare
- HQ
- Abingdon, United Kingdom
- Founded
- 2021
- Employees
- 8
- Website
- thirtyfivebio.com/
- Ownership
- Privately Held (backing)
ThirtyFiveBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ThirtyFiveBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ThirtyFiveBio in its N-PORT filings yet. We sweep new filings monthly.